ROOTSTOWN, Ohio--(BUSINESS WIRE)--As BioMendics prepares to share its progress during the 2026 J.P. Morgan Healthcare Conference and Biotech Showcase, the Ohio-based biotech is advancing what could ...
ROOTSTOWN, Ohio, August 07, 2025--(BUSINESS WIRE)--BioMendics, a clinical-stage biopharmaceutical company focused on rare skin diseases, today announced the launch of the TAMES-02 clinical trial—a ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with epidermolysis bullosa simplex treated with ...
BM-3103 is a first-in-class topical mTOR inhibitor that promotes autophagy to clear mutant keratin aggregates in epidermolysis bullosa simplex. The Food and Drug Administration (FDA) has granted Fast ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Diacerein 1% did not outperform vehicle in study ...
VANCOUVER, British Columbia, Feb. 3, 2015 /PRNewswire/ -- InMed Pharmaceuticals Inc. ("InMed") (CSE: IN; OTCQB: IMLFF) announced today that it has added a new therapy to its pipeline: INM-750, for the ...
The four main types of epidermolysis bullosa (EB): dystrophic epidermolysis bullosa (DEB), epidermolysis bullosa simplex (EBS), junctional epidermolysis bullosa (JEB) and Kindler syndrome (KS) are ...
Most children can't wait to play outside in the sunny summer days. But little Blake Kenyon longs for winter - because of a rare health condition that causes his skin to blister in the heat. The ...
As BioMendics prepares to share its progress during the 2026 J.P. Morgan Healthcare Conference and Biotech Showcase, the Ohio-based biotech is advancing what could become the first disease-modifying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results